The early detection of cervical cancer. The current and changing landscape of cervical disease detection
Open Access
- 17 April 2020
- journal article
- review article
- Published by Wiley in Cytopathology
- Vol. 31 (4) , 258-270
Abstract
Cervical cancer prevention has undergone dramatic changes over the past decade. With the introduction of human papillomavirus (HPV) vaccination, some countries have seen a dramatic decline in HPV‐mediated cervical disease. However, widespread implementation has been limited by economic considerations and the varying healthcare priorities of different countries, as well as by vaccine availability and, in some instances, vaccine hesitancy amongst the population/government. In this environment, it is clear that cervical screening will retain a critical role in the prevention of cervical cancer and will in due course need to adapt to the changing incidence of HPV‐associated neoplasia. Cervical screening has, for many years, been performed using Papanicolaou staining of cytology samples. As our understanding of the role of HPV in cervical cancer progression has advanced, and with the availability of sensitive detection systems, cervical screening now incorporates HPV testing. Although such tests improve disease detection, they are not specific, and cannot discriminate high‐grade from low‐grade disease. This has necessitated the development of effective triage approaches to stratify HPV‐positive women according to their risk of cancer progression. Although cytology triage remains the mainstay of screening, novel strategies under evaluation include DNA methylation, biomarker detection and the incorporation of artificial intelligence systems to detect cervical abnormalities. These tests, which can be partially anchored in a molecular understanding of HPV pathogenesis, will enhance the sensitivity of disease detection and improve patient outcomes. This review will provide insight on these innovative methodologies while explaining their scientific basis drawing from our understanding of HPV tumour biology.Keywords
Funding Information
- Medical Research Council Canada (MR/S024409/1)
This publication has 76 references indexed in Scilit:
- Screening for Cervical Cancer Precursors With p16/Ki-67 Dual-Stained Cytology: Results of the PALMS StudyJNCI: Journal of the National Cancer Institute, 2013
- The Biology and Life-Cycle of Human PapillomavirusesVaccine, 2012
- Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trialThe Lancet Oncology, 2012
- RNAscopeThe Journal of Molecular Diagnostics, 2012
- Evaluation of 14 triage strategies for HPV DNA‐positive women in population‐based cervical screeningInternational Journal of Cancer, 2011
- MicroRNA Expression Variability in Human Cervical TissuesPLOS ONE, 2010
- Immunocytochemical detection of HPV16 E7 in cervical smearExperimental & Molecular Medicine, 2007
- CK17 and p16 expression patterns distinguish (atypical) immature squamous metaplasia from high‐grade cervical intraepithelial neoplasia (CIN III)Histopathology, 2007
- Viral oncoproteins target the DNA methyltransferasesOncogene, 2006
- The cervical cancer epidemic that screening has prevented in the UKThe Lancet, 2004